Trevi Therapeutics (TRVI) News Today $7.26 +0.05 (+0.69%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.22 -0.04 (-0.55%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High - Time to Buy?August 30 at 6:25 AM | marketbeat.comInvesco Ltd. Acquires 829,364 Shares of Trevi Therapeutics, Inc. $TRVIAugust 30 at 3:30 AM | marketbeat.comTrevi spikes as B. Riley reportedly cites deal prospectsAugust 28 at 10:53 AM | msn.comAffinity Asset Advisors LLC Takes $7.86 Million Position in Trevi Therapeutics, Inc. $TRVIAugust 28 at 9:02 AM | marketbeat.comTrevi Therapeutics to Participate in Upcoming September ConferencesAugust 28 at 7:30 AM | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Morgan StanleyAugust 24, 2025 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Morgan StanleyAugust 23, 2025 | marketbeat.comMorgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationAugust 22, 2025 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $20.38 Average Price Target from AnalystsAugust 20, 2025 | americanbankingnews.comB. Riley Boosts Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | marketbeat.comB. Riley Increases Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco LtdAugust 17, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsAugust 16, 2025 | marketbeat.comPersistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comInformed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comTrevi Therapeutics: Optimism Amid Earnings Call InsightsAugust 13, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)August 13, 2025 | theglobeandmail.comHC Wainwright Analysts Increase Earnings Estimates for TRVIAugust 12, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSAugust 11, 2025 | marketbeat.comRaymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock PriceAugust 10, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansAugust 10, 2025 | finance.yahoo.comNeedham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00August 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comTrevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | prnewswire.com41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbHAugust 4, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in JulyAugust 2, 2025 | marketbeat.comTrevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on ThursdayAugust 2, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What HappenedAugust 1, 2025 | marketbeat.comTrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025July 31, 2025 | prnewswire.comTrevi Therapeutics to Participate in Upcoming August ConferencesJuly 29, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Time to Buy?July 24, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?July 9, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?July 3, 2025 | marketbeat.comAnalysts Offer Predictions for TRVI FY2025 EarningsJuly 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationJuly 2, 2025 | msn.comTRVI Trevi Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comCantor Fitzgerald Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)July 1, 2025 | marketbeat.comTrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 1, 2025 | prnewswire.comTRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the FirmJune 26, 2025 | globenewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Down 4% - Time to Sell?June 25, 2025 | marketbeat.comTRVI - Trevi Therapeutics Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMTrevi Therapeutics Stockholders Approve Key AmendmentsJune 17, 2025 | tipranks.comLeerink Partnrs Has Bullish Forecast for TRVI Q2 EarningsJune 13, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)June 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLCJune 7, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenJune 6, 2025 | marketbeat.comTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5, 2025 | prnewswire.comAmeriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)June 5, 2025 | marketbeat.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.691.05▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼75▲TRVI Articles Average Week Get the Latest News and Ratings for TRVI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Trevi Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MIRM News MLTX News PTGX News APLS News MENS News MTSR News SRRK News KYMR News AMRX News XENE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
